Sierra Oncology Company

Sierra Oncology, Inc., a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive splenic volume reduction and constitutional symptom control.

Funding Status: IPO
Number Of Exists: N/A
Employee Number: 51-100
Technology: Drug Design
Founded Date: 2004
Headquarters: Vancouver, British Columbia, Canada
Investment Stage: N/A
Industry: Drug Discovery
Investor Type: Undisclosed